← Leaderboards
Faye Johnson
University Of Tx Md Anderson Can Ctr
$4,125,981
Attributed
$8,036,492
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2010–24$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,036,492 · 4
By mechanism
R01$8,036,492 · 4
Top collaborators
- Mitchell J. Frederick5 shared
- Jagannadha K Sastry5 shared
- Andrew Sikora3 shared
- David John Tweardy3 shared
- Filip Janku2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- John V. Heymach$11,138,593
- Heath Devin Skinner$8,539,031
- Mitchell J. Frederick$5,632,139
- Lauren Averett Byers$9,117,683
- Abdullah Ali Osman$1,994,753
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsResponseCessation Of LifeIn VitroMalignant NeoplasmsHead And Neck Squamous Cell CarcinomaProteinsPharmaceutical PreparationsPathway InteractionsMediatingIn VivoCell DeathSurvival RateGrowthRecurrencePharmacodynamicsDrug KineticsNeoplastic CellTumorResistanceCancer CellLeadMouse ModelAurora B Kinase
Grant awards (18)
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$410,323
R01 · FY2024 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers$352,047
R01 · FY2024 · CA · contact PI
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$657,573
R01 · FY2023 · CA
Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)$637,606
R01 · FY2023 · CA · contact PI
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers$363,164
R01 · FY2023 · CA · contact PI
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$671,730
R01 · FY2022 · CA
Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)$637,606
R01 · FY2022 · CA · contact PI
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers$363,164
R01 · FY2022 · CA · contact PI
Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)$650,759
R01 · FY2021 · CA · contact PI
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers$370,575
R01 · FY2021 · CA · contact PI
Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)$650,759
R01 · FY2020 · CA · contact PI
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers$370,575
R01 · FY2020 · CA · contact PI
Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)$666,259
R01 · FY2019 · CA · contact PI
Targeting c-Src in Head and Neck Cancer$242,327
R01 · FY2014 · CA · contact PI
Targeting c-Src in Head and Neck Cancer$234,833
R01 · FY2013 · CA · contact PI
Targeting c-Src in Head and Neck Cancer$249,822
R01 · FY2012 · CA · contact PI
Targeting c-Src in Head and Neck Cancer$249,822
R01 · FY2011 · CA · contact PI
Targeting c-Src in Head and Neck Cancer$257,548
R01 · FY2010 · CA · contact PI